[1] |
YOU Rongli, HUANG Yurong, MAORui, HAI Lina, WANG Yingli, WANG Yan.
Mechanism of compound kushen injection in the treatment of lung cancer based on serum metabolomics and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 988-999.
|
[2] |
HOU Qiong, LIU Fei, CHEN Chuanrong.
Immunotherapy combined with anti-angiogenic drugs and chemotherapy in negative driver gene and advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 775-779.
|
[3] |
FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan.
miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
|
[4] |
ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun.
Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
|
[5] |
ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin.
Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
|
[6] |
LI Fei, DING Huiqin, CHEN Mengjing.
Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
|
[7] |
LIU Jiajun, QUE Zujun, TIAN Jianhui.
Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
|
[8] |
SU Yang, ZHOU Feng, DING Jinlei.
Effects of esketamine combined with sufentanil on postoperative analgesia and emotion after thoracoscopic radical resection of lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 59-65.
|
[9] |
HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle.
Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
|
[10] |
ZHANG Kexin, JIA Wenjing, CUI Jiawen, AO Luyao, ZHOU Fang, WANG Guangji, LIU Jiali.
Advances in the research and clinical application of the third generation EGFR TKIs in the treatment of non-small cell lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1016-1030.
|
[11] |
WANG Lin, LI Chongyang, LI Shuaihu, GAO Shenghan, XU Tian, LI Fei.
Research progress on pathogenic fusion gene in lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 877-885.
|
[12] |
CUI Hua, YAN Hongxia, YIN Mei.
Effects of down-regulating lncRNA LINC00176 on cisplatin resistance and autophagy in lung cancer A549/DDP cells
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 616-623.
|
[13] |
HUANG Yiting, SHEN Aizong.
Clinical research progress of afatinib therapy for lung cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
|
[14] |
LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun.
Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
|
[15] |
PEI Qinghua, SUN Jianli.
Research progress of Osimertinib acquired resistance
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 105-112.
|